{
    "clinical_study": {
        "@rank": "163221", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "description": "placebo"
            }, 
            {
                "arm_group_label": "stannsoporfin 1.5 mg/kg", 
                "description": "received 1.5 mg/kg in study 202"
            }, 
            {
                "arm_group_label": "stannsoporfin3.0 mg/kg", 
                "description": "received 1.5 mg/kg in study 202"
            }, 
            {
                "arm_group_label": "stannsoporfin 4.5 mg/kg", 
                "description": "stannsoporfin 4.5 mg/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "Follow-up, Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202"
        }, 
        "brief_title": "Follow-up, Blinded-Outcomes Trial of Subjects Having Received IMP in Clinical Trial 64,185-202", 
        "condition": [
            "Jaundice", 
            "Neonatal Hyperbilirubinemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperbilirubinemia", 
                "Jaundice", 
                "Hyperbilirubinemia, Neonatal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have received IMP in clinical trial 64,185-202 \u2022 Written informed\n             consent provided by parents/guardians\n\n        Exclusion Criteria:\n\n          -  na"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "4 Years", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects who have received stansaporfin in clinical trial 64,185-202"
            }
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033096", 
            "org_study_id": "64,185-203"
        }, 
        "intervention": {
            "arm_group_label": [
                "stannsoporfin 1.5 mg/kg", 
                "stannsoporfin3.0 mg/kg", 
                "stannsoporfin 4.5 mg/kg"
            ], 
            "intervention_name": "stannsoporfin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tin mesoporphyrin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "stannsoporfin", 
            "hyperbilirubinemia", 
            "heme oxygenase"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "number_of_groups": "4", 
        "official_title": "A 4-Year Follow-up, Blinded-Outcomes Trial of Subjects Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202 Trial Number: 64,185-203 Trial Phase:", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "long term effects of stannsoporfin treatment on adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "48 to 54 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033096"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "InfaCare Pharmaceuticals Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InfaCare Pharmaceuticals Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}